Corrigendum: FXYD5/Dysadherin, a biomarker of endometrial cancer myometrial invasion and aggressiveness: its relationship with TGF-β1 and NF-κB pathways

Front Oncol. 2024 Jan 23:13:1322204. doi: 10.3389/fonc.2023.1322204. eCollection 2023.

¹ Laboratorio de Estudios de la Interacción Celular en Reproducción y Cáncer, Instituto de Biología y Medicina Experimental (IBYME; CONICET-FIBYME), Buenos Aires, Argentina.
² Biomedical Research Group in Gynecology, Vall d'Hebron Research Institute (VHIR), Universitat Autónoma de Barcelona, CIBERONC, Barcelona, Spain.
³ Laboratorio de Mecanismos Moleculares de Carcinogénesis, Instituto de Biología y Medicina Experimental (IBYME; CONICET-FIBYME), Buenos Aires, Argentina.
⁴ Gynecological Oncology Department, Vall Hebron University Hospital, CIBERONC, Barcelona, Spain.
⁵ Hospital Italiano de Buenos Aires, Buenos Aires, Argentina.

Abstract

[This corrects the article DOI: 10.3389/fonc.2019.01306.].

Keywords: CCL-2; E-cadherin; FXYD5; NF-κB; TGF-β1; dysadherin; endometrial cancer.